Please note, this OEL/ADE monograph also applies to dextropropoxyphene hydrochloride (CAS RN 1639-60-7), dextropropoxyphene napsylate (CAS RN 26570-10-5), dextropropoxyphene napsylate anhydrous (CAS RN 17140-78-2), and dextropropoxyphene pamoate (CAS RN Not Available). Dextropropoxyphene is an opioid narcotic analgesic that is structurally related to methadone. The drug is often referred to as the general form “propoxyphene”; however, only the dextro-isomer (dextropropoxyphene or d-propoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect. Dextropropoxyphene is a pain reliever prescribed for the treatment of mild to moderate pain. The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have recommended that all dextropropoxyphene-containing preparations be no longer available in the Europe (EU) and United States of America (USA) based on safety reasons, although such preparations may be on the market in other countries.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Dextropropoxyphene, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.